Matthew Kapusta Sells 14,581 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 14,581 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the sale, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at $5,985,561.48. This represents a 2.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

uniQure Stock Performance

Shares of QURE opened at $14.27 on Friday. The business has a 50-day simple moving average of $22.04 and a two-hundred day simple moving average of $29.53. The company has a quick ratio of 7.12, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure N.V. has a 52 week low of $7.76 and a 52 week high of $71.50. The stock has a market cap of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on QURE. Stifel Nicolaus set a $14.00 price target on shares of uniQure in a research report on Monday, March 2nd. TD Cowen restated a “buy” rating on shares of uniQure in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Wolfe Research began coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Sanford C. Bernstein cut uniQure to a “market perform” rating in a report on Tuesday. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $34.33.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA purchased a new position in shares of uniQure in the third quarter worth $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new position in uniQure during the third quarter valued at $50,000. Torren Management LLC bought a new stake in uniQure in the 4th quarter valued at $28,000. Finally, FNY Investment Advisers LLC increased its holdings in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo?controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back?and?forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class?action and shareholder?lawsuit notices filed and circulated by law firms (lead?plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell?side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single?digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short?term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT?130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.